Education
The SURMOUNT-MAINTAIN trial answers what happens after you stop Mounjaro or Zepbound — and offers a lower-dose maintenance option that mostly held weight off.
Tirzepatide — the drug you know as Mounjaro for diabetes and Zepbound for weight loss — has produced some of the biggest weight-loss numbers we have ever seen. But everyone asks the same question: what happens when you stop? A new trial called SURMOUNT-MAINTAIN, published in The Lancet, finally gives us a clean answer. People who continued the drug kept most of the weight off. People who stopped regained much of it back.
In this episode:
• The full SURMOUNT-MAINTAIN trial design — 441 adults, three groups
• How the full dose, the 5 mg maintenance dose, and placebo compared at week 112
• Why obesity behaves like a long-term condition — not a short-term problem
• The "weight set point" — and why your body fights to climb back up
• When a lower maintenance dose might be the smarter long-term choice
• Important limitation — people with type 2 diabetes were NOT in this trial
Key takeaway: For tirzepatide to keep working, it likely needs to stay on board long-term. Maintenance dosing is now a real, evidence-backed option — but never stop, lower, or restart on your own.
Disclaimer: This podcast is for general education only. It is not medical advice. Always consult your doctor.
#Tirzepatide #Mounjaro #Zepbound #WeightLoss #SURMOUNTMAINTAIN #GLP1 #Obesity #WeightMaintenance #Lancet #MedicalNewsUpdate